dc.contributor.author
Ferrer Fábrega, Joana
dc.contributor.author
Folch i Puy, Emma
dc.contributor.author
Lozano Salvatella, Juan José
dc.contributor.author
Ventura Aguiar, Pedro
dc.contributor.author
Cárdenas, Gabriel
dc.contributor.author
Paredes, David
dc.contributor.author
García Criado, Ángeles
dc.contributor.author
Bombí, Josep Antoni
dc.contributor.author
García Pérez, Rocío
dc.contributor.author
López Boado, Miguel Ángel
dc.contributor.author
Rull, Ramón
dc.contributor.author
Esmatjes Mompó, Enric
dc.contributor.author
Ricart Brulles, Ma. José
dc.contributor.author
Diekmann, Fritz
dc.contributor.author
Fondevila Campo, Constantino
dc.contributor.author
Fernández Cruz, Laureano
dc.contributor.author
Fuster Obregón, Josep
dc.contributor.author
García-Valdecasas Salgado, Juan Carlos
dc.date.issued
2022-05-13T07:27:08Z
dc.date.issued
2022-05-13T07:27:08Z
dc.date.issued
2022-03-28
dc.date.issued
2022-05-13T07:27:08Z
dc.identifier
https://hdl.handle.net/2445/185546
dc.description.abstract
Due to the high vulnerability of the pancreas to ischemia-reperfusion injury, choices regarding preservation solution markedly affect pancreas transplant success. A retrospective single-center analysis of 380 pancreas transplants (2000-2019) was performed to correlate current preservation solutions with transplant outcomes. Early graft failure requiring transplantectomy within 30 days post-transplant occurred in 7.5% for University of Wisconsin (UW) group (n = 267), 10.8% of Celsior (CS) group (n = 83), 28.5% of Histidine-Tryptophan-Ketoglutarate (HTK) group (n = 7), and none for Institut Georges Lopez-1 (IGL-1) group (n = 23). The most common causes of technical failures in this cohort included abdominal hemorrhage (8.4%); graft pancreatitis (3.7%); fluid collections (2.6%); intestinal complications (6.6%); and vascular thrombosis (20.5%). Although IGL-1 solution provided lower surgical complication rates, no significant differences were found between studied groups. Nevertheless, HTK solution was associated with elevated pancreatitis rates. The best graft survival was achieved at 1 year using UW and IGL-1, and at 3 and 5 years using IGL-1 (p = 0.017). There were no significant differences in patient survival after a median follow-up of 118.4 months. In this setting therefore, IGL-1solution appears promising for perfusion and organ preservation in clinical pancreas transplantation, compared to other commonly used solutions. Keywords: pancreas transplantation, graft survival, preservation solution, ischemia-reperfusion, pancreatitis,
dc.format
application/pdf
dc.publisher
Frontiers Media
dc.relation
Reproducció del document publicat a: https://doi.org/10.3389/ti.2022.10419
dc.relation
Transplant International, 2022, vol. 35, num. 10419
dc.relation
https://doi.org/10.3389/ti.2022.10419
dc.rights
cc-by (c) Ferrer Fábrega, Joana et al., 2022
dc.rights
https://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Cirurgia i Especialitats Medicoquirúrgiques)
dc.subject
Trasplantament d'òrgans
dc.subject
Conservació d'òrgans
dc.subject
Transplantation of organs
dc.subject
Preservation of organs
dc.title
Current Trends in organ preservation solutions for pancreas transplantation; a single.center retrospective study
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion